NewsDesk @bactiman63 Specialty vaccine company, Valneva, announced the signing of a new $32 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of its...

NewsDesk @bactiman63 Specialty vaccine company, Valneva, announced that the U.S. Food and Drug Administration (FDA) has completed a filing review of its Biologics License Application for Valneva’s single-shot...

By NewsDesk  @bactiman63 Vaccine company, Valneva, announced Monday positive antibody persistence data twelve months after vaccination with a single dose of its chikungunya vaccine candidate, VLA1553. Following...

NewsDesk @bactiman63 Pfizer Inc. and Valneva SE announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy,...

NewsDesk @bactiman63 On Friday, Valneva and Pfizer reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer plan to proceed...

By NewsDesk  @infectiousdiseasenews Vaccine company, Valneva and Pfizer today announced further positive Phase 2 results, including booster response, for Lyme disease vaccine candidate VLA15. The Phase...

Specialty vaccine company, Valneva, announced positive topline results from the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. VLA1553 was recently awarded Breakthrough...

By NewsDesk  @infectiousdiseasenews Specialty vaccine company, Valneva announced recently it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553,...

Vaccine company, Valneva, announced that it has completed recruitment for the pivotal Phase 3 trial, VLA1553-301, of its single-shot chikungunya vaccine candidate, VLA1553. The sponsor of the first chikungunya...

Valneva SE and Pfizer Inc. announced Monday the initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies, incorporates new dose regimens and is anticipated to be the...